# ARB, ACEi, DRi Effects on COVID-19 Course Disease

> **NCT04364984** · — · COMPLETED · sponsor: **Medical Practice Prof D. Ivanov** · enrollment: 112 (actual)

## Conditions studied

- Hypertension
- COVID-19

## Interventions

- **DRUG:** Angiotensin converting enzyme inhibitor
- **DRUG:** Angiotensin Receptor Blockers
- **DRUG:** Direct renin inhibitor

## Key facts

- **NCT ID:** NCT04364984
- **Lead sponsor:** Medical Practice Prof D. Ivanov
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-01
- **Primary completion:** 2021-07-24
- **Final completion:** 2021-08-01
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364984, "ARB, ACEi, DRi Effects on COVID-19 Course Disease". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04364984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*